PTJ
TGTX icon

Paul Tudor Jones’s TG Therapeutics TGTX Stock Holding History

Paul Tudor Jones’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.16M Buy
+93,920
New +$3.84M 0.01% 1259
2026
Q1 		– Sell
-96,609
Closed -$2.88M – 4268
2025
Q4 		$2.88M Buy
96,609
+20,527
+27% +$670K 0.01% 1545
2025
Q3 		$2.75M Buy
+76,082
New +$2.51M ﹤0.01% 1605
2025
Q2 		– Sell
-84,475
Closed -$3.14M – 3747
2025
Q1 		$3.33M Buy
+84,475
New +$2.84M 0.01% 1010
2024
Q3 		– Sell
-83,092
Closed -$1.48M – 3104
2024
Q2 		$1.48M Sell
83,092
-71,404
-46% -$1.14M 0.01% 1250
2024
Q1 		$2.35M Buy
154,496
+112,661
+269% +$1.79M 0.01% 946
2023
Q4 		$715K Sell
41,835
-52,825
-56% -$614K 0.01% 1608
2023
Q3 		$791K Buy
+94,660
New +$1.32M 0.01% 1427
2022
Q4 		– Sell
-44,841
Closed -$265K – 2845
2022
Q3 		$265K Buy
+44,841
New +$294K 0.01% 1876
2021
Q4 		– Sell
-15,300
Closed -$509K – 3008
2021
Q3 		$509K Sell
15,300
-4,524
-23% -$140K 0.01% 1637
2021
Q2 		$769K Buy
+19,824
New +$778K 0.01% 972
2021
Q1 		– Sell
-15,983
Closed -$831K – 1851
2020
Q4 		$831K Buy
+15,983
New +$540K 0.02% 757
2020
Q2 		– Sell
-16,160
Closed -$159K – 1415
2020
Q1 		$159K Buy
+16,160
New +$204K 0.01% 870
2019
Q2 		– Sell
-34,196
Closed -$275K – 1334
2019
Q1 		$275K Buy
+34,196
New +$185K 0.01% 885
2017
Q4 		– Sell
-17,848
Closed -$211K – 1273
2017
Q3 		$211K Buy
+17,848
New +$203K 0.01% 943
2016
Q3 		– Sell
-23,516
Closed -$143K – 1727
2016
Q2 		$143K Buy
+23,516
New +$191K ﹤0.01% 1471

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Paul Tudor Jones's TGTX Position: Q2 2026 in Review

Paul Tudor Jones opened a new position in TG Therapeutics (TGTX) in Q2 2026: 93,920 shares worth $5.16M. The stake represents 0.01% of the portfolio and ranks #1259 among its holdings. This is a return to the name: Paul Tudor Jones previously reported a position in TGTX as recently as Q4 2025.

Paul Tudor Jones first reported a position in TGTX in Q2 2016 and has held it in 16 quarters since. 426 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Paul Tudor Jones held 93,920 shares of TG Therapeutics worth $5.16M as of Q2 2026.
  • TG Therapeutics was a new Paul Tudor Jones position in Q2 2026.
  • TG Therapeutics made up 0.01% of Paul Tudor Jones's portfolio in Q2 2026, its #1259 holding.
  • Paul Tudor Jones first reported a position in TG Therapeutics in Q2 2016 and has held it in 16 quarters since.
  • 426 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.